Lumexa Imaging (NASDAQ:LMRI – Get Free Report) and Chemed (NYSE:CHE – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.
Analyst Ratings
This is a summary of current ratings and recommmendations for Lumexa Imaging and Chemed, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lumexa Imaging | 1 | 0 | 4 | 2 | 3.00 |
| Chemed | 0 | 4 | 3 | 0 | 2.43 |
Lumexa Imaging presently has a consensus price target of $18.17, indicating a potential upside of 27.57%. Chemed has a consensus price target of $603.00, indicating a potential upside of 9.79%. Given Lumexa Imaging’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Lumexa Imaging is more favorable than Chemed.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Lumexa Imaging | -1.96% | -2.89% | -0.98% |
| Chemed | 10.61% | 35.18% | 19.43% |
Insider and Institutional Ownership
95.8% of Chemed shares are owned by institutional investors. 0.7% of Lumexa Imaging shares are owned by insiders. Comparatively, 3.3% of Chemed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Lumexa Imaging and Chemed”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lumexa Imaging | $267.73 million | 5.11 | -$47.10 million | ($0.54) | -26.37 |
| Chemed | $2.53 billion | 2.83 | $265.24 million | $20.90 | 26.28 |
Chemed has higher revenue and earnings than Lumexa Imaging. Lumexa Imaging is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.
Summary
Chemed beats Lumexa Imaging on 9 of the 14 factors compared between the two stocks.
About Lumexa Imaging
Lumexa Imaging operates outpatient diagnostic imaging centers that provide radiology services to patients, referring physicians and healthcare providers. Its services include imaging used to help diagnose and monitor a range of medical conditions. The company offers diagnostic procedures such as MRI, CT, PET/CT, mammography, ultrasound and X-ray through its imaging centers and affiliated radiology practices. Lumexa serves communities across the United States, providing an outpatient option for medical imaging outside of a hospital setting.
About Chemed
Chemed Corporation is a U.S.-based company operating through two principal businesses: VITAS Healthcare, which provides hospice and palliative care, and Roto-Rooter, which offers plumbing, drain-cleaning and water-restoration services. VITAS serves patients with serious illnesses through home-based care and services in hospice facilities and other care settings. Roto-Rooter serves residential and commercial customers with plumbing and drain services, as well as cleanup and restoration following water damage.
Receive News & Ratings for Lumexa Imaging Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumexa Imaging and related companies with MarketBeat.com's FREE daily email newsletter.
